Health crisis in Venezuela: Status of communicable diseases and implications for the European union and European economic area, may 2019
Espinosa, L., Mirinaviciute, G.
Yellow fever in the diagnostics laboratory review-article
Domingo, C., Charrel, R.N., Schmidt-Chanasit, J., Zeller, H., Reusken, C.
Mapping the burden of cholera in sub-Saharan Africa and implications for control: an analysis of data across geographical scales
Lessler, J., Moore, S.M., Luquero, F.J., McKay, H.S., Grais, R., Henkens, M., Mengel, M., Dunoyer, J., M'bangombe, M., Lee, E.C., Djingarey, M.H., Sudre, B., Bompangue, D., Fraser, R.S.M., Abubakar, A., Perea, W., Legros, D., Azman, A.S.
Increased risk of yellow fever infections among unvaccinated European travellers due to ongoing outbreak in Brazil, july 2017 to March 2018
Gossner, C.M., Haussig, J.M., de Bellegarde de Saint Lary, C., Kaasik Aaslav, K., Schlagenhauf, P., Sudre, B.
Monitoring and assessing vaccine safety: A European perspective
Lopalco, P. L., Johansen, K., Ciancio, B., De Carvalho Gomes, H., Kramarz, P., Giesecke, J.
No association found between pandemic influenza vaccination and Guillain-Barre Syndrome in EuropeArchived
Due to an association that was observed in the United States between a swine-flu based human influenza vaccine developed in 1976 and the disease acute polyneuropathy Guillain-Barré syndrome (GBS) (1,2), GBS was one of the adverse events that was monitored in Europe and North America (3) following the 2009 influenza pandemic vaccination campaigns.
Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: Multinational case-control study in Europe
Dieleman, J., Romio, S., Johansen, K., Weibel, D., Bonhoeffer, J., Sturkenboom, M.
An Inactivated Cell-Culture Vaccine against Yellow FeverArchived
A double-blind, placebo-controlled, dose-escalation, phase 1 study was performed in 60 healthy subjects between 18 and 49 years of age. The two-dose regimen induced the development of neutralizing antibodies in high percentages of the subjects (from 88% to 100% of subjects depending on antigen content)”.
Preventing and controlling disease outbreaks in a complex emergency situation: discussion of the tsunami aftermath.
Eurosurveillance Editorial Team
Prevention and control measures for yellow fever
A safe, effective and inexpensive yellow fever attenuated vaccine, known as YF 17D, has been used for more than half a century. The vaccine is highly effective. Travelers to endemic areas are advised to check their vaccination status and get vaccinated if necessary.